Prednisolone acetate

Identification

Summary

Prednisolone acetate is a glucocorticoid used to treat a wide variety of endocrine, inflammatory, and immune conditions as well as for palliation of neoplastic conditions.

Brand Names

Blephamide, Econopred Plus, Flo-pred, Pred Forte, Pred Mild, Pred-G

Generic Name

Prednisolone acetate

DrugBank Accession Number

DB15566

Background

Prednisolone acetate is a prednisolone molecule bound to an acetate functional group by an ester bond.⁵

Prednisolone acetate was granted FDA approval in 1955.⁵

Type

Small Molecule

Groups

Approved, Vet approved

Structure

Similar Structures

Weight: Average: 402.4807
Monoisotopic: 402.204238692
Chemical Formula: C₂₃H₃₀O₆

Synonyms

Prednisolone acetate

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Prednisolone acetate is indicated as an anti-inflammatory or immunosuppressive agent for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, or infectious conditions.⁵ Prednisolone acetate is also indicated in organ transplant patients, as well as endocrine or neoplastic conditions.⁵

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Patient Characteristics	Dose Form
Used in combination to treat	Eye inflammation	Combination Product in combination with: Sulfacetamide (DB00634)	••••••••••••	•••• •• ••••••••• •••••• •••••••••	•••••••••• • •••••
Used in combination to treat	Eye inflammation	Combination Product in combination with: Sulfacetamide (DB00634)	••••••••••••	••••••••••• •••••• ••••••••••	•••••••••• • •••••
Treatment of	Inflammation		••••••••••••
Management of	Inflammatory conditions		••••••••••••
Used in combination to treat	Ocular infections, irritations and inflammations	Combination Product in combination with: Gatifloxacin (DB01044)	••••••••••••		••••••

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals.⁴ Prednisolone acetate has a short duration of action as the half life is 2-3 hours.⁵ Corticosteroids have a wide therapeutic window as patients make require doses that are multiples of what the body naturally produces.⁴ Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.⁴

Mechanism of action

The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation.⁴ Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days.⁴

Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10.⁴

Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive.⁴ High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.⁴

Target	Actions	Organism
AGlucocorticoid receptor	agonist	Humans

Absorption

Prednisolone acetate oral suspension given at a dose equivalent to 15mg prednisolone has a C_max of 321.1ng/hr, a T_maxof 1-2 hours, and an AUC of 1999.4ng*hr/mL.⁵ The absorption pharmacokinetics of prednisolone acetate are not significantly different from a comparable dose of prednisolone.⁵

Volume of distribution

The volume of distribution of the active metabolite, prednisolone, is 0.22/0.7L/kg.⁵

Protein binding

The active metabolite, prednisolone, is 70-90% protein bound in plasma.⁵

Metabolism

Prednisolone acetate undergoes ester hydrolysis to prednisolone.¹ After this step, the drug undergoes the normal metabolism of prednisolone.

Prednisolone can be reversibly metabolized to prednisone which is then metabolized to 17α,21-dihydroxy-pregnan-1,4,6-trien-3,11,30-trione (M-XVII), 20α-dihydro-prednisone (M-V), 6βhydroxy-prednisone (M-XII), 6α-hydroxy-prednisone (M-XIII), or 20β-dihydro-prednisone (M-IV).² 20β-dihydro-prednisone is metabolized to 17α,20ξ,21-trihydroxy-5ξ-pregn-1-en-3,11-dione(M-XVIII).² Prednisolone is metabolized to Δ6-prednisolone (M-XI), 20α-dihydro-prednisolone (M-III), 20β-dihydro-prednisolone (M-II), 6αhydroxy-prednisolone (M-VII), or 6βhydroxy-prednisolone(M-VI).² 6αhydroxy-prednisolone is metabolized to 6α,11β,17α,20β,21-pentahydroxypregnan-1,4-diene-3-one (M-X).² 6βhydroxy-prednisolone is metabolized to 6β,11β,17α,20β,21-pentahydroxypregnan-1,4-diene-3-one (M-VIII), 6β,11β,17α,20α,21-pentahydroxypregnan-1,4-diene-3-one (M-IX), and 6β,11β,17α,21-tetrahydroxy-5ξ-pregn-1-en-3,20-dione (M-XIV).² MVIII is metabolized to 6β,11β,17α,20β,21-pentahydroxy-5ξ-pregn-1-en-3-one (M-XV) and then to MXIV, while MIX is metabolized to 6β,11β,17α,20α,21-pentahydroxy-5ξ-pregn-1-en-3-one (M-XVI) and then to MXIV.² These metabolites and their glucuronide conjugates are excreted predominantly in the urine.^2,5

Hover over products below to view reaction partners

Prednisolone acetate
- Prednisolone

Route of elimination

Prednisolone acetate is predominantly excreted in the urine.⁵

Half-life

Oral prednisolone acetate has a plasma half life of 2-3 hours.⁵

Clearance

Data regarding the clearance of prednisolone acetate is not readily available.^6,7,8

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

The oral LD₅₀ of prednisolone acetate in mice is 1680 mg/kg.⁸ Patients experiencing an overdose of oral prednisolone acetate may experience an increased severity in the adverse effects of corticosteroids.⁵ Overdose of oral prednisolone acetate may be treated by gastric lavage or inducing vomiting if the overdose was recent, as well as supportive and symptomatic therapy.⁵ Chronic overdosage may be treated by dose reduction or treating patients on alternate days.⁵ An overdose by the ophthalmic route is not expected to cause problems.⁵

Pathways

Not Available

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Abametapir	The serum concentration of Prednisolone acetate can be increased when it is combined with Abametapir.
Abemaciclib	The metabolism of Abemaciclib can be increased when combined with Prednisolone acetate.
Acalabrutinib	The metabolism of Acalabrutinib can be increased when combined with Prednisolone acetate.
Acarbose	The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Acarbose.
Aceclofenac	The risk or severity of gastrointestinal irritation can be increased when Prednisolone acetate is combined with Aceclofenac.

Food Interactions

Avoid excessive or chronic alcohol consumption. Alcohol may cause gastric irritation.
Take with food. Food reduces gastrointestinal irritation.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Ak Tate Oph Sus 1%	Suspension	1 %	Ophthalmic	Sandoz Canada Incorporated	1985-12-31	2008-08-07
Diopred Suspension 1%	Suspension	1 %	Ophthalmic	Sandoz Canada Incorporated	1994-12-31	Not applicable
Econopred	Suspension	1.25 mg/1	Ophthalmic	ALCON LABORATORIES, INC.	2006-09-13	Not applicable
Econopred	Suspension	10 mg/10mL	Ophthalmic	Physicians Total Care, Inc.	1994-05-05	2011-05-31
Econopred	Suspension	10 mg/1mg	Ophthalmic	ALCON LABORATORIES, INC.	1973-07-10	2007-12-31

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Prednisolone Acetate	Suspension / drops	10 mg/1	Ophthalmic	REMEDYREPACK INC.	2013-02-06	2015-05-12
Prednisolone Acetate	Suspension / drops	10 mg/1mL	Ophthalmic	Asclemed Usa, Inc.	1997-08-19	Not applicable
Prednisolone Acetate	Suspension / drops	10 mg/1mL	Ophthalmic	Nucare Pharmaceuticals,inc.	1997-08-19	2019-12-31
Prednisolone Acetate	Suspension / drops	10 mg/1mL	Ophthalmic	Pacific Pharma, Inc.	1997-08-19	Not applicable
Prednisolone Acetate	Suspension / drops	10 mg/1mL	Ophthalmic	A-S Medication Solutions	1997-08-19	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Blephamide	Prednisolone acetate (2 mg/1mL) + Sulfacetamide sodium (100 mg/1mL)	Suspension / drops	Ophthalmic	A-S Medication Solutions LLC	1961-10-01	Not applicable
Blephamide	Prednisolone acetate (0.2 %) + Sulfacetamide sodium (10 %)	Solution / drops	Ophthalmic	Allergan	1989-12-31	2022-01-21
Blephamide	Prednisolone acetate (2 mg/1g) + Sulfacetamide sodium (100 mg/1g)	Ointment	Ophthalmic	Allergan, Inc.	1987-01-01	Not applicable
Blephamide	Prednisolone acetate (2 mg/1g) + Sulfacetamide sodium (100 mg/1g)	Ointment	Ophthalmic	A-S Medication Solutions LLC	1987-01-01	Not applicable
Blephamide	Prednisolone acetate (2 mg/1g) + Sulfacetamide sodium (100 mg/1g)	Ointment	Ophthalmic	Physicians Total Care, Inc.	2012-03-04	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Ixoba M	Prednisolone acetate (10 mg/1mL) + Ketorolac tromethamine (5 mg/1mL) + Moxifloxacin hydrochloride monohydrate (5 mg/1mL)	Kit	Ophthalmic	Brisk Pharmaceuticals, Inc.	2021-08-26	Not applicable
Pred-Brom	Prednisolone acetate (10 mg/1mL) + Bromfenac sodium (0.75 mg/1mL)	Suspension / drops	Ophthalmic	Imprimis Njof, Llc	2018-01-05	Not applicable
Pred-Brom	Prednisolone acetate (10 mg/1mL) + Bromfenac (0.75 mg/1mL)	Suspension / drops	Ophthalmic	ImprimisRx NJ	2018-02-01	Not applicable
Pred-Gati	Prednisolone acetate (10 mg/1mL) + Gatifloxacin sesquihydrate (5 mg/1mL)	Suspension / drops	Ophthalmic	Imprimis Njof, Llc	2018-01-05	2019-07-01
Pred-Gati	Prednisolone acetate (10 mg/1mL) + Gatifloxacin hemihydrate (5 mg/1mL)	Suspension	Ophthalmic	ImprimisRx NJ	2018-03-01	Not applicable

Chemical Identifiers

UNII: 8B2807733D
CAS number: 52-21-1
InChI Key: LRJOMUJRLNCICJ-JZYPGELDSA-N
InChI: InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h6,8,10,16-18,20,26,28H,4-5,7,9,11-12H2,1-3H3/t16-,17-,18-,20+,21-,22-,23-/m0/s1
IUPAC Name: 2-[(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl acetate
SMILES: [H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

References

General References

Musson DG, Bidgood AM, Olejnik O: Assay methodology for prednisolone, prednisolone acetate and prednisolone sodium phosphate in rabbit aqueous humor and ocular physiological solutions. J Chromatogr. 1991 Apr 19;565(1-2):89-102. doi: 10.1016/0378-4347(91)80373-k. [Article]
Matabosch X, Pozo OJ, Perez-Mana C, Papaseit E, Segura J, Ventura R: Detection and characterization of prednisolone metabolites in human urine by LC-MS/MS. J Mass Spectrom. 2015 Mar;50(3):633-42. doi: 10.1002/jms.3571. [Article]
Doppenschmitt SA, Scheidel B, Harrison F, Surmann JP: Simultaneous determination of prednisolone, prednisolone acetate and hydrocortisone in human serum by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1995 Dec 15;674(2):237-46. doi: 10.1016/0378-4347(95)00317-7. [Article]
Yasir M, Sonthalia S: Corticosteroid Adverse Effects . [Article]
FDA Approved Drug Products: Prednisolone Acetate Oral Suspension [Link]
FDA Approved Drug Products: Prednisolone Acetate Ophthalmic Suspension [Link]
FDA Approved Drug Products: Prednisolone Acetate Ophthalmic Suspension 1% [Link]
Greenstone LLC: Prednisolone Acetate Ophthalmic Suspension MSDS [Link]

External Links

KEGG Compound: C08180
PubChem Compound: 5834
ChemSpider: 5629
ChEBI: 8380
ChEMBL: CHEMBL1152
ZINC: ZINC000003875348
Wikipedia: Prednisolone_acetate

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
4	Active Not Recruiting	Treatment	Corneal Transplant / Grafting, Corneal / Keratoplasty, Lamellar / Transplantation, Cornea	1
4	Active Not Recruiting	Treatment	Pterygium of Both Eyes	1
4	Completed	Not Available	Cataract Surgery	1
4	Completed	Not Available	Cataracts	1
4	Completed	Not Available	Macula Thickening	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Ointment	Ophthalmic
Solution / drops	Ophthalmic
Ointment	Ophthalmic; Topical
Suspension	Ophthalmic	1.25 mg/1
Suspension	Ophthalmic	10 mg/1mg
Suspension	Ophthalmic	10 mg/10mL
Suspension / drops	Ophthalmic
Suspension	Ophthalmic	1 %
Suspension	Oral	16.7 mg/5mL
Suspension	Oral	5 mg/5mL
Kit	Ophthalmic
Injection	Intra-articular; Intramuscular
Solution	Ophthalmic
Suspension / drops	Ophthalmic
Suspension / drops	Ophthalmic	1 %
Solution	Ophthalmic	10 mg/ml
Suspension	Ophthalmic	1 % w/v
Solution / drops	Ophthalmic	0.12 %
Suspension / drops	Ophthalmic	1.2 mg/1mL
Suspension	Ophthalmic	10.000 mg
Suspension	Ophthalmic
Suspension	Conjunctival; Ophthalmic	1000000 mg
Suspension	Ophthalmic	1.2 mg
Suspension / drops	Ophthalmic	10 mg/ml
Suspension	Ophthalmic	10 mg/1mL
Suspension / drops	Ophthalmic	10 mg/1
Suspension / drops	Ophthalmic	10 mg/1mL
Injection	Intra-articular; Intramuscular	25 mg/ml
Injection, suspension	Intramuscular
Suspension	Conjunctival; Ophthalmic	10 mg
Suspension	Ophthalmic	0.12 %
Suspension	Ophthalmic	10 mg
Suspension	Ophthalmic	10.0000 mg
Suspension	Ophthalmic	1000000 mg
Suspension	Ophthalmic	1.2 mg
Solution / drops	Ophthalmic	0.5 %
Solution, gel forming / drops	Intraocular	0.5 g
Suspension	Conjunctival; Ophthalmic
Suspension	Conjunctival; Ophthalmic	5 mg
Suspension	Intraocular; Ophthalmic
Liquid	Ophthalmic	10 mg/1ml

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US7799331	No	2010-09-21	2028-10-11
US6071523	No	2000-06-06	2018-06-03
US6399079	No	2002-06-04	2018-06-03
US5881926	No	1999-03-16	2016-03-16
US6656482	No	2003-12-02	2018-06-03

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	238	ChemSpider
logP	1.332	ChemSpider

Predicted Properties

Property	Value	Source
Water Solubility	0.0417 mg/mL	ALOGPS
logP	2.17	ALOGPS
logP	1.71	Chemaxon
logS	-4	ALOGPS
pKa (Strongest Acidic)	12.61	Chemaxon
pKa (Strongest Basic)	-2.9	Chemaxon
Physiological Charge	0	Chemaxon
Hydrogen Acceptor Count	5	Chemaxon
Hydrogen Donor Count	2	Chemaxon
Polar Surface Area	100.9 Å²	Chemaxon
Rotatable Bond Count	4	Chemaxon
Refractivity	107.64 m³·mol^-1	Chemaxon
Polarizability	42.93 Å³	Chemaxon
Number of Rings	4	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	splash10-000i-0797000000-836ba07555e28d36300f
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	splash10-00dj-2950000000-e2793b767fd6fd52b223
MS/MS Spectrum - , positive	LC-MS/MS	splash10-000i-0797000000-836ba07555e28d36300f
MS/MS Spectrum - , positive	LC-MS/MS	splash10-00dj-2950000000-e2793b767fd6fd52b223
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0f9i-0019200000-95c380920a55764fab5d
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0k96-9104400000-f69d937affa03380d2cf
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0gw3-0879200000-7afd20339a4cada1cb23
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0a4i-9007100000-10862352a1c548ab8a61
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0pba-9063000000-e3c9dc37563eb39ef5f0
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0229-0922000000-1073d2960d78897860ec
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å²)	Source type	Source
[M-H]-	205.3036396	predicted	DarkChem Lite v0.1.0
[M-H]-	197.31555	predicted	DeepCCS 1.0 (2019)
[M+H]+	205.0126396	predicted	DarkChem Lite v0.1.0
[M+H]+	199.21097	predicted	DeepCCS 1.0 (2019)
[M+Na]+	204.6210396	predicted	DarkChem Lite v0.1.0
[M+Na]+	205.86543	predicted	DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. Glucocorticoid receptor

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Agonist

General Function: Zinc ion binding
Specific Function: Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name: NR3C1
Uniprot ID: P04150
Uniprot Name: Glucocorticoid receptor
Molecular Weight: 85658.57 Da

References

Ikonomidis I, Tzortzis S, Lekakis J, Paraskevaidis I, Andreadou I, Nikolaou M, Kaplanoglou T, Katsimbri P, Skarantavos G, Soucacos P, Kremastinos DT: Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart. 2009 Sep;95(18):1502-7. doi: 10.1136/hrt.2009.168971. Epub 2009 May 28. [Article]
Boudinot FD, D'Ambrosio R, Jusko WJ: Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm. 1986 Oct;14(5):469-93. [Article]

Enzymes

Details1. Cytochrome P450 3A4

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate
Inducer

General Function: Vitamin d3 25-hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name: CYP3A4
Uniprot ID: P08684
Uniprot Name: Cytochrome P450 3A4
Molecular Weight: 57342.67 Da

References

Usui T, Saitoh Y, Komada F: Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7. doi: 10.1248/bpb.26.510. [Article]
Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P: Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol. 1992 Jun;41(6):1047-55. [Article]
Litt J. (2016). Litt's Drug eruption & reaction manual (22nd ed.). CRC Press LLc.

Carriers

Details1. Corticosteroid-binding globulin

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Binder

General Function: Steroid binding
Specific Function: Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name: SERPINA6
Uniprot ID: P08185
Uniprot Name: Corticosteroid-binding globulin
Molecular Weight: 45140.49 Da

References

Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
Frey BM, Frey FJ: Estimation of transcortin concentration by measurements of plasma protein-binding of prednisolone and by electroimmunodiffusion. Br J Clin Pharmacol. 1982 Feb;13(2):245-9. [Article]
Ko HC, Almon RR, Jusko WJ: Effect of corticosteroid binding globulin on the pharmacokinetics of prednisolone in rats. Pharm Res. 1995 Jun;12(6):902-4. [Article]
Angeli A, Frajria R, De Paoli R, Fonzo D, Ceresa F: Diurnal variation of prednisolone binding to serum corticosteroid-binding globulin in man. Clin Pharmacol Ther. 1978 Jan;23(1):47-53. [Article]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]

Details2. Serum albumin

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Binder

General Function: Toxic substance binding
Specific Function: Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name: ALB
Uniprot ID: P02768
Uniprot Name: Serum albumin
Molecular Weight: 69365.94 Da

References

Czock D, Keller F, Rasche FM, Haussler U: Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98. doi: 10.2165/00003088-200544010-00003. [Article]

Transporters

Details1. Solute carrier organic anion transporter family member 1A2

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Sodium-independent organic anion transmembrane transporter activity
Specific Function: Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name: SLCO1A2
Uniprot ID: P46721
Uniprot Name: Solute carrier organic anion transporter family member 1A2
Molecular Weight: 74144.105 Da

References

Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [Article]

Details2. P-glycoprotein 1

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate

General Function: Xenobiotic-transporting atpase activity
Specific Function: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name: ABCB1
Uniprot ID: P08183
Uniprot Name: Multidrug resistance protein 1
Molecular Weight: 141477.255 Da

References

Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [Article]
Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [Article]

Drug created at October 23, 2019 21:18 / Updated at February 20, 2024 23:55

Prednisolone acetate

Identification

Structure for Prednisolone acetate (DB15566)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Collision Cross Sections (CCS)

Targets

References

Enzymes

References

Carriers

References

References

Transporters

References

References